•  
  •  
  •  
  •  

2025-12-08 01:41:47

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • AFCOM forays into Australian and Pacific Region countries with the Strategic Relationship of Nauru Air Corporation of Republic of Nauru
  • Ola Electric Commences Mass Deliveries of 4680 Bharat Cell Powered Vehicles
  • Delhivery Completes Successful Testing of its Autonomous Logistics Drone in Deoria
  • P N Gadgil Jewellers Ltd opens new store at Patna
  • Sai Silks Kalamandir Ltd opens its 75th store at Mysore

Keywords Selected:  INE326A01037

Research

  • Lupin - Q1FY23 Result Update - Margin disappointment continues - HOLD

Stock Report

  • Lupin receives tentative approval from U.S. FDA for Siponimod Tablets
  • Lupin and Valorum Enter into an Exclusive Licensing Agreement for Biosimilar Armlupeg™ in the United States
  • Lupin Receives Approval from U.S. FDA for Biosimilar Armlupeg - Pegfilgrastim-unne
  • Lupin Foundation Earns CRISIL's Highest VO 1A Rating for Excellence in Social Responsibility
  • Lupin Ltd receives 7 observations from USFDA for Goa manufacturing facility
  • Lupin announces closure of Inspection by U.S. FDA at its Nagpur Unit-1 Facility with No Observations
  • Lupin Launches Risperidone Long-Acting Injectable with 180-day CGT exclusivity in the U.S.
  • Lupin Establishes a New Global Standard in Sustainable Pharma with an S&P Global ESG Score of 91
  • Lupin Receives EIR from U.S. FDA for its Aurangabad (CSN) Facility
  • Lupin Manufacturing Solutions Unveils Dedicated Oncology Block at Vizag, India
  • Lupin Bioresearch Center receives Zero Observations from U.S. FDA after Successful Inspection and Assessment
  • Lupin Digital Health Launches VITALYFE™
  • Lupin Launches Authorized Generic Version of Ravicti® in the United States
  • Lupin Announces Presentation of Phase 1 Data on LNP3693 (STING agonist) at the ESMO Congress 2025
  • Lupin gets one observation from USFDA for Somerset, New Jersey manufacturing facility
  • Lupin unveils Strategic Partnership Program to Expand Reach of its Long-Acting Injectable Platform
  • Lupin Launches Liraglutide Injection in the United States
  • Lupin Launches Rivaroxaban for Oral Suspension in the United States
  • Lupin receives approval from U.S. FDA for Rivaroxaban for Oral Suspension
  • Lupin Strengthens its Global Specialty Ophthalmology Business with acquisition of VISUfarma from GHO Capital
  • Lupin gets 4 observations from USFDA from PAI at Pune Biotech facility
  • Lupin receives approval from U.S. FDA for Lenalidomide Capsules
  • Lupin receives 6 observations from USFDA for Nagpur Injectable facility
  • USFDA conducts product specific pre-approval inspection at Lupin Ltd's Aurangabad facility

Latest Post

  • AFCOM forays into Australian and Pacific Region countries with the Strategic Relationship of Nauru Air Corporation of Republic of Nauru
  • Ola Electric Commences Mass Deliveries of 4680 Bharat Cell Powered Vehicles
  • Delhivery Completes Successful Testing of its Autonomous Logistics Drone in Deoria
  • P N Gadgil Jewellers Ltd opens new store at Patna
  • Sai Silks Kalamandir Ltd opens its 75th store at Mysore


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2024